TWiV 1030: Clinical update with Dr. Daniel Griffin
This Week in Virology · VIncent Racaniello
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In his weekly clinical update, Dr. Griffin discusses the use of RSV vaccines in older adults: recommendations of the advisory committee on immunization practices, case report of leprosy in Central Florida, blood group A enhances SARS-CoV-2 infection, predicting COVID-19 incidence using wastewater surveillance data, a common allele of HLA associated with asymptomatic SARS-CoV-2 infection, prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-reported COVID-19 symptoms in the phase 3 move-out trial, Molnupiravir for treatment of adults with mild or moderate COVID-19, delayed intubation associated with in-hospital mortality in patients with COVID-19 respiratory failure who fail heated and humified high flow nasal canula, relationship between azithromycin and cardiovascular outcomes in unvaccinated patients with COVID‐19 and preexisting cardiovascular disease, and the effects of COVID-19 on cognitive performance in a community-based cohort, clinical phenotypes and quality of life to define post-COVID-19 syndrome.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Use of RSV vaccines in older adults (CDC)
- Case report of leprosy in Central Florida (EID)
- Blood group A enhances SARS-CoV-2 infection (Blood)
- Predicting COVID-19 incidence using wastewater surveillance data (EID)
- Common allele of HLA associated with asymptomatic SARS-CoV-2 infection (Nature)
- Prevalence of low-frequency antiviral resistance variants in SARS-CoV-2 isolates (JAMA)
- Viral resistance analyses from the Remdesivir phase 3 treatment trial (JID)
- Impact of Molnupiravir treatment on patient-reported COVID-19 symptoms (CID)
- Molnupiravir for treatment of adults with mild or moderate COVID-19 (CMI)
- Delayed intubation associated with in-hospital mortality in patients with COVID-19 (BMC)
- Relationship between Azithromycin and cardiovascular outcomes in unvaccinated patients with COVID‐19 (JAHA)
- The effects of COVID-19 on cognitive performance in a community-based cohort (eClinical)
- Clinical phenotypes and quality of life to define post-COVID-19 syndrome (eClinical)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1030
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]